SRC
GCVRZ

Shufro Rose & Co’s Sanofi Contingent Value Rights GCVRZ Stock Holding History

Shufro Rose & Co’s Portfolio GCVRZ Stock Details GCVRZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,872
Closed -$1K – 359
2019
Q3 		$1K Buy
+1,872
New +$1.01K ﹤0.01% 339

Other funds holding GCVRZ

SCM
Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return
EM
Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return
MCM
Mason Capital Management New York $613M AUM 21.43% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
WA
Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return
NGA
New Generation Advisors Manchester, Massachusetts $45.6M AUM 15.43% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
MFP
Michael F. Price $846M AUM 0.07% 1-Year Est. Return

Shufro Rose & Co's GCVRZ Position: Q4 2019 in Review

Shufro Rose & Co sold out of Sanofi Contingent Value Rights (GCVRZ) in Q4 2019, closing a stake of 1,872 shares — an estimated $1K sold.

Shufro Rose & Co first reported a position in GCVRZ in Q3 2019 and held it in 1 quarter. The position peaked at $1K in Q3 2019. 103 funds tracked by Wall St. Rank hold GCVRZ as of Q4 2019.

  • Shufro Rose & Co reported no remaining Sanofi Contingent Value Rights position as of Q4 2019 after selling out during the quarter.
  • Shufro Rose & Co sold 1,872 Sanofi Contingent Value Rights shares in Q4 2019, an estimated $1K.
  • Shufro Rose & Co first reported a position in Sanofi Contingent Value Rights in Q3 2019 and held it in 1 quarter.
  • Shufro Rose & Co's Sanofi Contingent Value Rights position peaked at $1K in Q3 2019.
  • 103 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q4 2019.

Based on Shufro Rose & Co's 13F filing for Q4 2019, filed 28 Jan 2020.